![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CST5 |
Gene summary for CST5 |
![]() |
Gene information | Species | Human | Gene symbol | CST5 | Gene ID | 1473 |
Gene name | cystatin D | |
Gene Alias | CST5 | |
Cytomap | 20p11.21 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P28325 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1473 | CST5 | GSM4909307 | Human | Breast | IDC | 2.82e-64 | 1.17e+00 | 0.1569 |
1473 | CST5 | GSM4909308 | Human | Breast | IDC | 5.61e-108 | 1.50e+00 | 0.158 |
1473 | CST5 | M5 | Human | Breast | IDC | 4.93e-02 | 2.63e-01 | 0.1598 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Breast | ![]() | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ | ||
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005254714 | Breast | IDC | regulation of peptidase activity | 96/1434 | 461/18723 | 7.58e-20 | 6.15e-17 | 96 |
GO:005254814 | Breast | IDC | regulation of endopeptidase activity | 88/1434 | 432/18723 | 1.20e-17 | 4.85e-15 | 88 |
GO:004586114 | Breast | IDC | negative regulation of proteolysis | 70/1434 | 351/18723 | 8.21e-14 | 2.22e-11 | 70 |
GO:005134613 | Breast | IDC | negative regulation of hydrolase activity | 71/1434 | 379/18723 | 1.33e-12 | 2.90e-10 | 71 |
GO:001046613 | Breast | IDC | negative regulation of peptidase activity | 56/1434 | 262/18723 | 1.39e-12 | 2.92e-10 | 56 |
GO:001095112 | Breast | IDC | negative regulation of endopeptidase activity | 52/1434 | 252/18723 | 3.53e-11 | 5.57e-09 | 52 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CST5 | SNV | Missense_Mutation | c.184N>A | p.Asp62Asn | p.D62N | P28325 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-B6-A0RV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
CST5 | SNV | Missense_Mutation | novel | c.59N>T | p.Ala20Val | p.A20V | P28325 | protein_coding | deleterious(0.02) | benign(0.42) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CST5 | SNV | Missense_Mutation | c.41N>T | p.Ala14Val | p.A14V | P28325 | protein_coding | tolerated(0.32) | benign(0.005) | TCGA-AA-3819-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CST5 | SNV | Missense_Mutation | rs756477706 | c.20C>T | p.Thr7Ile | p.T7I | P28325 | protein_coding | tolerated(0.15) | benign(0) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CST5 | SNV | Missense_Mutation | novel | c.398N>T | p.Ser133Phe | p.S133F | P28325 | protein_coding | deleterious(0.01) | probably_damaging(0.922) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CST5 | SNV | Missense_Mutation | c.392N>C | p.Lys131Thr | p.K131T | P28325 | protein_coding | tolerated(0.67) | benign(0.067) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CST5 | SNV | Missense_Mutation | c.392N>C | p.Lys131Thr | p.K131T | P28325 | protein_coding | tolerated(0.67) | benign(0.067) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CST5 | SNV | Missense_Mutation | c.403C>A | p.Leu135Met | p.L135M | P28325 | protein_coding | tolerated(0.09) | possibly_damaging(0.493) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CST5 | SNV | Missense_Mutation | novel | c.401T>C | p.Ile134Thr | p.I134T | P28325 | protein_coding | deleterious(0) | benign(0.109) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CST5 | SNV | Missense_Mutation | c.275N>A | p.Arg92Gln | p.R92Q | P28325 | protein_coding | deleterious(0.04) | probably_damaging(0.939) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1473 | CST5 | PROTEASE INHIBITOR, DRUGGABLE GENOME | Tumor necrosis factor alpha (TNF-alpha) inhibitors |
Page: 1 |